key: cord-0882054-qhq3slti
authors: Angel, Luis; Kon, Zachary N.; Chang, Stephanie H.; Rafeq, Samaan; Shekar, Saketh Palasamudram; Mitzman, Brian; Amoroso, Nancy; Goldenberg, Ronald; Sureau, Kimberly; Smith, Deane; Cerfolio, Robert J.
title: Novel Percutaneous Tracheostomy for Critically Ill Patients with COVID-19
date: 2020-04-25
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2020.04.010
sha: 36ea71f8435bdaa8bdd7dabe5f731127fe72bdcb
doc_id: 882054
cord_uid: qhq3slti

Abstract Background COVID-19 is a worldwide pandemic, with many patients requiring prolonged mechanical ventilation. Tracheostomy is not recommended by current guidelines as it is considered a super-spreading event due to aerosolization that unduly risks healthcare workers. Methods Patients with severe COVID-19 that were on mechanical ventilation ≥ 5 days were evaluated for percutaneous dilational tracheostomy. We developed a novel percutaneous tracheostomy technique that placed the bronchoscope alongside the endotracheal tube, not inside it. This improved visualization during the procedure and continued standard mechanical ventilation after positioning the inflated endotracheal tube cuff in the distal trachea. This technique offers a significant mitigation for the risk of virus aerosolization during the procedure. Results From March 10 to April 15, 2020, 270 patients with COVID-19 required invasive mechanical ventilation at New York University Langone Health Manhattan’s campus of which 98 patients underwent percutaneous dilational tracheostomy. The mean time from intubation to the procedure was 10.6 days (SD ±5 days). Currently, thirty-two (33%) patients do not require mechanical ventilatory support, 19 (19%) have their tracheostomy tube downsized and 8 (8%) were decannulated. Forty (41%) patients remain on full ventilator support, while 19 (19%) are weaning from mechanical ventilation. Seven (7%) died as result of respiratory and multiorgan failure. Tracheostomy related bleeding was the most common complication (5 patients). None of health care providers have developed symptoms or tested positive for COVID-19. Conclusions Our percutaneous tracheostomy technique appears to be safe and effective for COVID-19 patients and safe for healthcare workers.

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, with over 2.4 million cases diagnosed to date. 1 While most COVID-19 patients will not require supportive care, 10-15% of patients develop acute respiratory distress that require invasive ventilatory support. 2, 3 Mechanical ventilation for patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a prolonged airway intubation and high worldwide mortality of at least 50-67%. [4] [5] [6] Based on the previous experience with severe acute respiratory syndrome (SARS) in 2003, aerosol-generating procedures such as tracheal intubation or performing tracheostomy were considered high-risk procedures for transmission of SARS-CoV-2 to healthcare workers. 7 The American Academy of Otolaryngology and the Ears, Nose, Throat Surgery in the United Kingdom, have stated providers should "avoid tracheotomy in COVID-19 positive or suspected patients" due to the risks to healthcare providers. These guidelines, based on limited evidence, recommend that tracheostomies should not be performed before 2-3 weeks after intubation, preferably after negative COVID-19 testing 8, 9 and recommend open tracheostomy placement in these circumstances as opposed to percutaneous dilational tracheostomy (PDT). An earlier tracheostomy for COVID-19 patients has potential advantages, therefore we developed a novel modification of the standard PDT procedure, designed to improve visualization and ventilation while minimizing the risk of aerosolization of SARS-CoV-2 to healthcare providers. In this paper, we describe the technical aspects of the procedure, detail early patient outcomes and evaluate the early safety of our technique to our healthcare providers.

We conducted an institutional analysis of all patients admitted to the intensive care unit (ICU) at New York University (NYU) Langone Health Care System's Manhattan campus from March 10 th , 2020 to April 15 th , 2020 who had confirmed COVID-19 as documented by nasal 4 pharyngeal swab for reverse transcriptase polymerase chain reaction (rtPCR) assay and who developed severe respiratory failure requiring mechanical ventilation. The NYU Langone institutional review board approved this study (IRB #120-00475).

The entry criteria for PDT were patients confirmed positive for COVID-19, on mechanical ventilation for five or more days with anticipated prolonged need for mechanical ventilation or placement on extracorporeal membranous oxygenation (ECMO) for more than one day; isolated respiratory failure except acute renal failure on dialysis or continuous renal replacement therapy. Mechanical ventilation settings recommended for the procedure were a positive endexpiratory pressure (PEEP) ≤ 12 mmHg, fraction of inspired oxygen (FiO 2 ) ≤ 60%, respiratory rate ≤25 breaths per minute and partial pressure of carbon dioxide (PaCO 2 ) ≤ 60 mmHg.

Exclusion criteria included patients with uncorrected coagulopathy, body mass index over 45 and/or multiorgan failure.

PDTs were performed at the bedside in the patient's ICU room. All personnel wore full personal protection equipment (PPE) per institutional policies (hair cover, N95 mask, surgical mask, face shield, gown, and two layers of gloves) upon entering the room. Team members spanned three roles: 1) performing the bronchoscopy, 2) placement of the tracheostomy and 3) operation of the ventilator, applying medication for sedation, and endotracheal tube management. The patient was placed supine with a shoulder roll in standard position for a percutaneous tracheostomy. Sedation and paralytics were given prior to the procedure ( Figure   1a and protocol available in the supplemental appendix) 5 An anterior neck ultrasound/doppler was performed with a linear probe to identify anatomical landmarks, vascular structures, and to mark the site of insertion between the first and second tracheal rings. Maximal oxygenation was performed prior to the procedure. The endotracheal tube (ETT) was freed from the holder, and the bronchoscope was inserted adjacent to the ETT and advanced to the level of the vocal cords ( Figure 1b) . The bronchoscope was advanced past the vocal cords, anterior to the ETT (Figure 1c ). With the ventilator on standby mode, we deflated the ETT cuff and advanced the ETT further into the distal trachea.

The ETT cuff was re-inflated and the ventilator restarted. We then performed the PDT. The needle and catheter were inserted into the airway under direct visualization ( Figure 1d ). The guidewire was threaded into the airway and directed caudally ( Figure 1e) . A superficial small (0.5 cm) skin incision was made after the wire was in place. The track was dilated with a short dilator then with the "Blue Rhino" dilator (COOK Medical) ( Figure 1f ). Before insertion of the tracheostomy tube, the ventilator was put on standby mode again, and the ETT cuff was deflated. The ETT was withdrawn under direct visualization until it was proximal to the tracheostomy site. A percutaneous tracheostomy tube Shiley TM Flexible Tracheostomy #8.5 (Covidien) was inserted into the trachea, the cuff was inflated, and the bronchoscope was advanced through the tracheostomy tube to confirm position and to remove any blood or secretions form the airway. The ventilator was then connected and restarted once the circuit was closed.

To improve access to the subglottic space, we used a therapeutic bronchoscope (Olympus America). This scope ensures enough torque and rigidity to maneuver around the ETT and "push through" the anterior space of the vocal cords. Secretions were suctioned from the mouth and retropharynx prior to bronchoscope insertion to improve visualization. Once the ETT is seen in the posterior aspect of the vocal cords, a "jaw thrust" maneuver with a posterior push on the ETT helped opening the space to facilitate passage of the bronchoscope.

The endpoints for this study were the safety and feasibility of our bedside PDT in mechanically ventilated patients with COVID-19, early patient outcomes, and early healthcare providers outcomes for COVID-19 symptoms and/or SARS-CoV-2 positive testing.

From March 10 th , 2020 to April 15 th , 2020, 270 patients were intubated and started on mechanical ventilation at the NYU Langone Health Manhattan campus. We had tracheostomy consults on 130 patients; 98 patients underwent a bedside PDT with our technique (Figure 2 ).

In the overall study population, the mean age was 57 years; 80 patients (82%) were men, the mean body mass index was 31 and at the time of intubation they had a severe respiratory failure with a mean PaO2/FiO 2 ratio of 132 (Table 1 ). The described technique was successful in 96 (98%) patients. In two patients receiving ECMO support with severe upper airways and subglottic edema, we could not provide adequate visualization during the procedure and they required a standard PDT approach; however, as they were on ECMO support we performed the PDT under apneic conditions. In the study population, once we accessed the subglottic space, the ETT cuff was in the subglottic space in 75% of patients, with frequent findings of inflammation and mucosal ischemic changes. Six additional patients were not candidates for PDT and underwent an open tracheostomy, at the bedside, by two otolaryngology attending physicians (2 patients with tracheal stenosis, 1 redo tracheostomy with calcified stoma, 2 patients with body mass index over 50, and one patient with innominate artery overlying the trachea superior to the sternal notch). 

Post-tracheostomy bleeding was present in five patients, all of whom were on therapeutic anticoagulation and three on ECMO support. Of those five patients, one required surgical exploration, which was a standard PDT. Two accidental tracheostomy tube removals occurred during the study, one by a patient and another by a health care provider.

The tracheostomy team included six physicians and two nurses who participated across the 98 bedside percutaneous tracheostomies. Four of these team members have agreed to testing and all have been negative via nasal pharyngeal swab for rtPCR assay testing. None have missed any days of work and to this date all continue to take care of patients and all are performing PDTs in additional patients. To date, none of these eight team members or additional nurses, respiratory and physical therapist providing care to these COVID-19 patients post tracheostomy has developed any symptoms of fever, general malaise, cough, shortness of breath and/or have tested positive for COVID-19.

From March 10 th , 2020 to April 15 th , 2020, we had 270 patients with SARS-CoV-2 infection admitted to the ICU with severe respiratory failure requiring invasive mechanical ventilation. Their respiratory failure, as previously reported, was prolonged with an average duration to this date of 18 days. We believed that an earlier tracheostomy provided the optimal care to these patients, who in addition to the severe respiratory failure, were also receiving high levels of sedation and/or paralysis, had major issues with increased airway secretions and limited access to respiratory and physical therapy as a result of the overwhelming number of patients on mechanical ventilation and the risk presented by SARS-CoV-2 to health care workers.

This study reports the feasibility of performing this novel technique for PDT in patients stricken with COVID-19. Of the 98 patients that fulfill the inclusion criteria appropriate for PDT, 96 (98%) were successfully performed, with the other two having severe subglottic edema required a standard approach to PDT. These two patients were on ECMO support and did not require ventilation during the procedure.

The early outcomes appear to support the multiple benefits of tracheostomy placement.

As shown in other series, tracheostomy may reduce the duration of mechanical ventilation requirement and lead to shorter ICU stays. 10, 11 The placement of a tracheostomy enables better management of secretions due to easier suctioning and the ability to change the inner cannula. This is a major benefit for patients with COVID-19. Due to improved comfort, heavy sedation can be weaned in patients with tracheostomy, 5 which has the added benefit of decreased use of paralytic agents and sedatives that were required in over 56% of these patients. Additionally, patients with a tracheostomy undergoing ventilator support weaning are more easily able to participate in respiratory therapy, physical therapy, and sit in a chair, contributing to faster recovery. While there was an 7% mortality rate, this early mortality report is significantly lower that the 50% to 67% reported in the literature on COVID-19 patients with respiratory failure requiring invasive mechanical respiratory support. [4] [5] [6] This reflects that our inclusion criteria selected the patients with the highest potential benefit from an early tracheostomy and survival.

In fact, 32 (33%) have already been weaned entirely off ventilator support, with 19 (19%) of those patients downsized and 8 (8%) decannulated from their tracheostomy tubes.

No intra-procedural complications were noted, and bleeding was minimized as we always performed an ultrasound with Doppler in the selected access area. Seventy-one patients (72%) that underwent PDT on were on therapeutic anticoagulation, of which five patients (5.1%) had bleeding within the first 48 hours of the procedure that required bedside packing around the tracheostomy, with one requiring surgical management. Another potential benefit of tracheostomies is the decreased incidence of tracheal stenosis in the subglottic space. 11 Two patients already had granulation tissue and subglottic stenosis present at time of bronchoscopy. After discharge from the ICU, all patients are followed by speech pathology and otolaryngology for final decannulation and independent evaluation of long-term complications.

A key finding of this study is that all providers who have participated in the bedside percutaneous tracheostomy procedures remain COVID-19 negative by symptoms and/or by testing. There was no conversion rate in the four (50%) who agreed to testing and no providers have developed any symptoms or have missed any workdays. All providers wore standard PPE.

We decreased the number of healthcare providers present in the room to three team members, minimized the amount of time with an open-air system to few seconds, and had no time with active ventilation/aerosolization during the open-air system. Compared with a standard bedside PDT, which has an open-air system with active ventilation/aerosolization through most of the procedure, this modified technique is beneficial in COVID-19 patients, due to the high risk for transmission with aerosolization of the virus. 12 The benefits to the patient must always be balanced against the risk to the provider, this technique moves towards optimizing the former without unnecessarily risking the latter.

Our paper has strengths and weaknesses. It is the largest report in the literature with 98 patients with COVID-19 patients on mechanical ventilation undergoing PDT. We also demonstrate a high success rate in performing this novel technique, with safe patient and health care provider outcomes and minimal post-procedural complications. Additionally, this study is the first description demonstrating how to perform a PDT that mitigates the aerosolization of SARS-CoV-2 during the procedure. Most importantly, the early outcomes reported supports that tracheostomies are beneficial for these patients and that PDT can be safely performed with low healthcare worker exposure to the virus. There are several flaws including the short duration of this initial report, with only early outcomes being available with an average follow-up of 18 days after starting mechanical ventilation. Also, not all health care workers providers involved in both in the procedure and the post procedure care have been tested by rtPCR or SARS-CoV-2 antibodies, and certain percent of COVID-19 infected people are asymptomatic; however, it is impossible to determine the value of a positive test, as daily testing was not feasible and the continuous high level of exposure during the five weeks of providing critically care to COVID-19 patients outside of the PDT procedures.

The described technique allows optimal COVID-19 patient care in the ICU, while minimizing the risk of infection for health care workers. The technique is described in detail and is easy to perform. This study supports that, at early review, both can be achieved. On a larger scale, the earlier weaning from mechanical ventilation may increase the number of available ICU beds and ventilators needed to adequately treat the large demands from these COVID-19

patients. Further follow-up studies on this cohort will evaluate late outcomes of this technique and evaluate its efficacy and value in patients with COVID-19. 

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 in New York City

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-2019) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control

ICNARC report on COVID-19 in critical care

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUS of the Lombardy region, Italy. JAMA

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Aerosol general procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

Tracheotomy recommendations during the COVID-19 pandemic. Airway and Swallowing Committee of the American Academy of Otolaryngology-Head and Neck Surgery

Guidance for surgical tracheostomy and tracheostomy tube change during the COVID-19 pandemic

Tracheotomy timing and outcomes in the critically ill

Early versus late tracheostomy for critically ill patients

Precautions for endoscopic transnasal skull base surgery during the COVID-19 pandemic. Neurosurg, in press